Italian ophthalmic pharmaceutical company SIFI is donating multiple products to the ophthalmology departments of the main Italian hospitals, including sterile products for the treatment of ocular discomfort and for the prevention of potential risks of infection.
As seen in the COVID-19 Guidelines published by the American Academy of Ophthalmology (AAO) “several reports suggest the virus can cause conjunctivitis and possibly be transmitted by aerosol contact with conjunctiva.1″ The first doctor in China to diagnose the novel coronavirus was in fact an ophthalmologist, and he managed to locate the infection in the membrane of the eyes of infected patients.
SIFI wishes to help, both in fighting and minimizing risks of eye infections during such a crisis, and also in alleviating possible symptoms of dry eye in the health personnel, engaged relentlessly and in extreme labor conditions.
“Our wish is to help Italy’s medical and healthcare workforce during these challenging times with a small but we hope significant gesture,” Fabrizio Chines, SIFI President and CEO, said in a company news release. “We want to show our support to the thousands of health professionals that are working to defeat the virus with skill, courage, and relentlessly stamina.”
SIFI designs, manufactures and markets innovative pharmaceutical specialty products, nutraceuticals, surgical and medical devices.
- AAO – Alert: Important coronavirus updates for ophthalmologists. Sources CDC, WHO https://www.aao.org/headline/alert-important-coronavirus-context